These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36607902)

  • 1. Effect of tirzepatide on prediabetics and blood pressure with implications for future research.
    Seetharaman R
    J Basic Clin Physiol Pharmacol; 2023 Mar; 34(2):243-244. PubMed ID: 36607902
    [No Abstract]   [Full Text] [Related]  

  • 2. Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.
    Chiu N; Aggarwal R; Bhatt DL
    J Am Heart Assoc; 2022 Aug; 11(16):e026297. PubMed ID: 35929468
    [No Abstract]   [Full Text] [Related]  

  • 3. New Drug Capsule: Tirzepatide.
    Beninger P
    Clin Ther; 2023 Mar; 45(3):300-301. PubMed ID: 36870873
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tirzepatide - A major breakthrough in the fight against obesity.
    Habiba U; Iqbal A; Kumar S
    J Pak Med Assoc; 2023 Mar; 73(3):741. PubMed ID: 36932808
    [No Abstract]   [Full Text] [Related]  

  • 6. Surpassing insulin glargine in type 2 diabetes with tirzepatide.
    Khoo B; Tan TM
    Lancet; 2021 Nov; 398(10313):1779-1781. PubMed ID: 34672968
    [No Abstract]   [Full Text] [Related]  

  • 7. Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.
    Patoulias D; Doumas M; Papadopoulos C
    Am J Cardiol; 2022 Jun; 173():157-158. PubMed ID: 35459459
    [No Abstract]   [Full Text] [Related]  

  • 8. Tirzepatide highly effective for weight loss.
    Tysoe O
    Nat Rev Endocrinol; 2022 Sep; 18(9):520. PubMed ID: 35760842
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
    Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirzepatide (Mounjaro) for type 2 diabetes.
    Med Lett Drugs Ther; 2022 Jul; 64(1654):105-107. PubMed ID: 35802842
    [No Abstract]   [Full Text] [Related]  

  • 11. The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
    Papachristou S; Popovic DS; Papanas N
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3503. PubMed ID: 34626443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tirzepatide to treat obesity: phase III results.
    Hindson J
    Nat Rev Gastroenterol Hepatol; 2022 Aug; 19(8):488. PubMed ID: 35773392
    [No Abstract]   [Full Text] [Related]  

  • 13. Tirzepatide: A New Anti-Obesity Medication.
    Ghoneim S
    Gastroenterology; 2023 Jan; 164(1):159. PubMed ID: 36155186
    [No Abstract]   [Full Text] [Related]  

  • 14. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
    Pirro V; Roth KD; Lin Y; Willency JA; Milligan PL; Wilson JM; Ruotolo G; Haupt A; Newgard CB; Duffin KL
    J Clin Endocrinol Metab; 2022 Jan; 107(2):363-378. PubMed ID: 34608929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirzepatide and kidney function: an intriguing and promising observation.
    Solini A
    Lancet Diabetes Endocrinol; 2022 Nov; 10(11):762-763. PubMed ID: 36152638
    [No Abstract]   [Full Text] [Related]  

  • 17. In type 2 diabetes, tirzepatide reduced HbA
    Gandhi GY
    Ann Intern Med; 2021 Nov; 174(11):JC127. PubMed ID: 34724396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
    Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
    J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks.
    Ebell MH
    Am Fam Physician; 2023 Jan; 107(1):99. PubMed ID: 36689986
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.